Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
09 août 2022 07h00 HE
|
Achilles Therapeutics PLC
- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 - - Cell & Gene Therapy Catapult manufacturing...
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
21 juil. 2022 08h00 HE
|
Achilles Therapeutics PLC
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board
30 juin 2022 08h00 HE
|
Achilles Therapeutics PLC
LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Recognized with the 2022 PING Innovation Award
21 juin 2022 08h30 HE
|
Achilles Therapeutics PLC
LONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
10 mai 2022 07h00 HE
|
Achilles Therapeutics PLC
- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS Cohort B) for metastatic malignant melanoma - ...
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
09 mai 2022 07h00 HE
|
Achilles Therapeutics PLC
- THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review - - Monotherapy data from higher-dose cohorts in both CHIRON and THETIS and combination data from...
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
04 mai 2022 08h00 HE
|
Achilles Therapeutics PLC
LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to Present at Upcoming Conferences
03 mai 2022 08h00 HE
|
Achilles Therapeutics PLC
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
12 avr. 2022 07h30 HE
|
Achilles Therapeutics PLC
– Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support future development – LONDON, April 12, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:...
Achilles Therapeutics to Present at Upcoming Conferences
05 avr. 2022 08h00 HE
|
Achilles Therapeutics PLC
LONDON, April 05, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...